Pfiz­er picks up ear­ly-stage ADC can­di­date cleared for sol­id tu­mor tri­als

Just days af­ter clos­ing its Seagen ac­qui­si­tion, Pfiz­er has struck a deal to ex­pand its an­ti­body-drug con­ju­gate port­fo­lio even fur­ther.

Nona Bio­sciences, the part­ner­ship-dri­ven an­ti­body shop launched by Har­bour Bio­Med, says Pfiz­er is li­cens­ing glob­al de­vel­op­ment and com­mer­cial­iza­tion rights to its mesothe­lin-tar­get­ed ADC, HBM9033.

Pfiz­er will hand over up to $53 mil­lion in up­front and near-term pay­ments while promis­ing mile­stones that can reach $1.05 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER